Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ase Industrial Holding Ltd ADR (NY: ASX )

11.07 +0.13 (+1.19%)
Streaming Delayed Price Updated: 11:08 AM EDT, May 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ase Industrial Holding Ltd ADR

< Previous 1 2 3 4 5 6 7 Next >
Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
From Virtual Investor Conferences
Via GlobeNewswire
ASE Technology Reports Mixed Q1 Performance, Margins Shrink
Via Benzinga
5 Value Stocks In The Technology Sector
Via Benzinga
Earnings Preview: ASE Technology Holding Co
Via Benzinga
Golden Cross Appears Before ASE Technology Holding Co Investors
Via Benzinga
Battery & Precious Metals Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
ASE wins Device Technology of the Year award for VIPack™
From Advanced Semiconductor Engineering, Inc.
Via Business Wire
ASE recognized for excellence by Texas Instruments
From Advanced Semiconductor Engineering, Inc.
Via Business Wire
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology
Wearable sensor parameters correlate strongly with clinical scales of motor impairment 
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Runway Growth Finance Corp. Provides First Quarter 2023 Portfolio Update
From Runway Growth Finance Corp.
Via GlobeNewswire
Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Pushpay’s Annual State of Church Tech Report Shows Refined Use of Ministry Tools Among Catholic Churches
New results reveal the significant role that technology and digital solutions now play among parishes and diocese nationwide 
From Pushpay
Via GlobeNewswire
Pushpay Announces New Product Innovations to Help Streamline Ministry Operations and Increase Engagement in the Church
From Pushpay
Via GlobeNewswire
Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
ASE Drives Latency and Bandwidth Innovation with VIPack™ Fanout Package-on-Package
From Advanced Semiconductor Engineering, Inc.
Via Business Wire
Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Pushpay’s Customer Success Team Wins Contact Center of the Year at the 2023 Stevie® Awards
Pushpay was recognized among three categories at the 17th annual Stevie® Awards for Sales and Customer Success 
From Pushpay
Via GlobeNewswire
Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Pushpay’s 2023 State of Technology Report Reveals Hybrid Church Is Here to Stay
Research surfaces the powerful role technology and digital solutions play in the faith sector today, and future aspirations of the Church 
From Pushpay
Via GlobeNewswire
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
From Amarin Corporation plc
Via GlobeNewswire
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
From uniQure Inc.
Via GlobeNewswire
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B
From uniQure Inc.
Via GlobeNewswire
Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Pushpay’s Women’s Leadership Exploration and Development Group to Host Public Event on International Women’s Day
“Bold Careers: Women Executives Discuss Their Authentic Journey” 
From Pushpay
Via GlobeNewswire
Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model
Independent Study Reports ATH434 Prevented Onset of Motor and Non-Motor Symptoms in Animals with Genetically Induced Parkinson’s disease 
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy
Recruitment ongoing in Europe, Asia-Pacific, and the U.S. for study of rapidly progressive Parkinsonian Disorder 
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
7 Top-Rated Chip Stocks for Your January Must-Buy List
Even as recession and 'tech slowdown' worries loom, now's the time to pounce on these seven chip-stocks to buy. 
Via InvestorPlace
ASE’s Bumping Factory in Kaohsiung, Taiwan inducted into the World Economic Forum’s Global Lighthouse Network
From Advanced Semiconductor Engineering, Inc.
Via Business Wire
ASE Technology Holding Achieves the Best Overall Performance on the Dow Jones Sustainability Indices, Semiconductors and Semi Equipment Industry Group
From ASE Technology Holding Co., Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.